Logotype for Tango Therapeutics Inc

Tango Therapeutics (TNGX) Study result summary

Event summary combining transcript, slides, and related documents.

Logotype for Tango Therapeutics Inc

Study result summary

8 Jun, 2026

Study background and rationale

  • Vopimetostat, an oral PRMT5 inhibitor, was evaluated in combination with pan-RAS inhibitors (daraxonrasib and zoldonrasib) in MTAP-deleted, RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), targeting a highly challenging malignancy.

  • Over 90% of pancreatic cancers harbor RAS mutations, making RAS inhibition a promising therapeutic strategy.

  • Preclinical and clinical studies demonstrated synergy between PRMT5 and RAS inhibition, supporting clinical investigation and maximal synergy with panRAS inhibitors.

  • The study included heavily pre-treated patients with MTAP loss, mostly with prior chemotherapy, and assessed both efficacy and safety.

  • The combination approach aims to provide a chemotherapy-free regimen for first-line pancreatic cancer treatment and patients with limited alternatives.

Study design and patient population

  • Ongoing Phase 1/2 trial enrolled 59 patients: 20 PDAC and 5 NSCLC received vopimetostat plus daraxonrasib; 34 PDAC received vopimetostat plus zoldonrasib.

  • Patients were heavily pre-treated, with over half receiving the combinations as third-line therapy.

  • Nearly all MTAP-deleted PDAC patients have co-occurring KRAS mutations, highlighting a large, high-need target population.

  • MTAP-deleted cancers represent 10-15% of all cancers and 40% of pancreatic cancers.

  • Approximately 60,000 patients in the US have MTAP-deleted metastatic cancers annually, with PDAC representing a significant portion.

Key clinical results / Efficacy results

  • Vopimetostat plus daraxonrasib in PDAC showed a 92% objective response rate (ORR), 90% six-month progression-free survival (PFS), and 100% disease control rate (DCR) in heavily pretreated patients.

  • Vopimetostat plus zoldonrasib in PDAC achieved a 52% ORR, 74% six-month PFS, and 96% DCR in KRAS G12D-mutant patients.

  • Combined ORR in 2/3L PDAC was 64%, with a combined DCR of 97%.

  • Responses were observed in both second- and third-line settings, with no meaningful difference in efficacy between these groups.

  • The combination also showed high activity in MTAP-deleted NSCLC, with a 93-100% ORR in a small cohort.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Tango Therapeutics